Endpoints for randomized controlled clinical trials for COVID-19 treatments

BACKGROUND: Endpoint choice for randomized controlled trials of treatments for novel coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments that can be used as part of the outbreak response, in the midst of considerable uncertainty and limited information...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Trials
Main Authors: Dodd, Lori E, Follmann, Dean, Wang, Jing, Koenig, Franz, Korn, Lisa L, Schoergenhofer, Christian, Proschan, Michael, Hunsberger, Sally, Bonnett, Tyler, Makowski, Mat, Belhadi, Drifa, Wang, Yeming, Cao, Bin, Mentre, France, Jaki, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611901/
https://ncbi.nlm.nih.gov/pubmed/32674594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774520939938
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados